Press Releases

Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary hemostatic gel, VETIGEL®, to be sold directly to veterinarians through Penn Veterinary Supply, an independent U.S. regional distributor of veterinary products and services. Cresilon's VETIGEL – a plant-based hemostatic gel that instantly stops and controls bleed

The Institute of International Trade along with FTCCI to organise the "Pharma and IP Workshop: Exploring Innovation and Intellectual Property in Pharmaceuticals on 16th August at Novotel HICC in Hyderabad. The workshop will be held in support of organisations such as KIIT-TBI TTO, Rohan Consultancy, LexOrbis, RVR Associates   The workshop will through insights into drug regulatory affairs, R & D Processes, Clinical Trials, Patentability, Trade Secrets and

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "Sanyou" hereafter) and Sinorda Biomedicine (referred to as " Sinorda " hereafter) have officially signed a strategic cooperation agreement to advance the innovative bispecific antibody drug project. According to the cooperation agreement, leveraging Sanyou's world-leading core technology platform for integrated R&D and preclinical development of innovative biological drugs, along with a world

the leading global nutraceuticals contract development and manufacturing organization (CDMO) – will launch two new softgels targeted at customers who look to innovate in the consumer health space at CPHI Barcelona. The new formulations are designed to meet the rising demand of consumers for products with more natural actives for both menopause and improved eye health. Sirio has held a European GMP license for the production of pharmaceutical softgels in its German manufacturin

Porosome Therapeutics, Inc. (Porosome Therapeutics) has announced the development of a radically new and distinctive therapeutic offering to treat cystic fibrosis, filing a comprehensive patent addressing the disorder and other health conditions. Porosome Therapeutics’ paradigm-shifting approach is the first therapeutic application of the porosome, the cell’s secretory apparatus. The approach addresses the cell's secretory machinery and water transport regulation to treat secr

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has accepted the filing of Geron’s New Drug Application (NDA) for imetelstat, its first-in-class telomerase inhibitor, for the treatment of transfusion-dependent anemia in patients with lower risk myelodysplastic syndromes (MDS). “The FDA’s acceptance of our New Drug Application is an important landmark along o

Körber and iocto have already been collaborating for over five years, which is why iocto received the "Certified" level for their “iocto MSI Core Framework” right from the beginning. The solutio  connects pharmaceutical control and monitoring systems with the Werum PAS-X MES Manufacturing Execution System via Körber’s Werum PAS-X MSI Plug & Produce interface. It enables the collection, integration, and transfer of data between equipment and MES a

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has approved INGREZZA® (valbenazine) capsules for the treatment of adults with chorea associated with Huntington's disease (HD).1 INGREZZA is the only selective vesicular monoamine transporter 2 (VMAT2) inhibitor that offers an effective starting dosage that can be adjusted by a patient's healthcare provider based on response and tolerability, with no complex titration.1 Only IN

Nagasaki University and NEC OncoImmunity (NOI), a leading artificial intelligence (AI) company, have announced that they will collaborate to use NOI's AI platform to design universal vaccines against highly pathogenic and tropical infectious diseases. The collaboration between NOI and Nagasaki University aims to harness the power of advanced AI to optimize vaccine designs to be universally and broadly protective against certain pathogen families prevalent in tropical regions. Un

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that it has completed the exclusive license of key assets from Deverra Therapeutics Inc. ("Deverra") related to its proprietary allogeneic stem cell expansion and directed differentiation platform for the generation of multiple distinct immune effector cell types, including natural killer (